A PHASE 3, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS • To compare the efficacy of CP-690,550 (5 mg BID & 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in subjects with moderate to severe chronic ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED PHASE 3, EFFICACY AND SAFETY STUDY OF SUNITINIB (SU011248) IN PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER TREATED WITH ERLOTINIB Primary Objective: • To demonstrate that the combination of sunitinib plus erlotinib is superior to erlotinib plus placebo in prolonging the overall survival for advanced/metastatic NSCLC patients who...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

SUNITINIB TREATMENT OF RENAL ADJUVANT CANCER (S-TRAC): A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF ADJUVANT SUNITINIB VS. PLACEBO IN SUBJECTS WITH HIGH RISK RCC To demonstrate an improvement in disease-free survival (DFS) in high risk (per modified UISS criteria) subjects with RCC randomly assigned to adjuvant sunitinib 50 mg schedule 4/2: 4 weeks on, 2 weeks...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study to test the safety and efficacy of Glasdegib (PF-04449913) versus placebo in patients with Myelofibrosis Lead-in Cohort • To assess the safety and tolerability of PF-04449913 in patients with primary or secondary MF who have been previously treated with ≥1 JAKi. Randomized Cohort • To compare...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A PHASE 3, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS • To compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in subjects with moderate to severe chroni...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SUNITINIB MALATE VERSUS SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA To demonstrate that OS on sunitinib is superior or equivalent to OS on sorafenib in patients with advanced hepatocellular carcinoma

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study to test efficacy, tolerability, safety and pharmacokinetics of Tofacitinib ointment in subjects with mild, moderate or severe chronic plaque psoriasis 1. To characterize the efficacy of tofacitinib ointment (10 mg/g and 20 mg/g) applied once daily (QD) or twice daily (BID) over 12 weeks in subjects with mild or moderate chronic plaque psoriasis comp...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study to test whether PF-05212377 is safe and improves symptoms in patients with Alzheimer's disease with existing neuropsychiatric symptoms. Estudio para probar si PF-05212377 es seguro y si mejora los síntomas en pacientes con enfermedad de Alzheimer que presentan síntomas neuropsiquiátricos To evaluate the efficacy of PF-05212377 (SAM-760) 30 mg QD as compared to placebo on the primary measure of cognition and memory, the Alzheimer?s Disease Assessment Scale ? cognitive subscale (13 item...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A clinical study to evaluate the effects and safety of three doses of Tofacitinib (a drug that is being investigated for the treatment of rheumatoid arthritis) in subjects with active Ankylosing spondylitis (AS) (a form of Arthritis) 1. To compare the efficacy of tofacitinib, in doses of 2 mg BID, 5 mg BID, 10 mg BID versus placebo on the ASAS20 response rate at Week 12 in subjects with active AS that have had an inadequate respon...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB IN METASTATIC COLORECTAL CANCER PATIENTS RECEIVING IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFIRI) AS FIRST LINE TREATMENT To demonstrate that the combination of FOLFIRI plus sunitinib is superior to FOLFIRI plus placebo in prolonging the progression-free survival (PFS) in the first-line treatment of patients with metasta...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune